Venture Capital Archives - Boston Life Sciences Times

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

December 13, 2025

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

December 12, 2025

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

December 11, 2025

THIS WEEK'S STORIES

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

December 11, 2025

Vertex Showcases New CASGEVY Data, Including First Results in Children Ages 5–11, and Prepares Global Regulatory Filings

December 8, 2025

Phare Bio and Basilea form partnership to develop AI-designed broad-spectrum antibiotic

December 11, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Venture Capital

Cosette Pharmaceuticals Terminates Agreement to Acquire Mayne Pharma

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

Allonnia raises more than $20 million to accelerate deployment of materials biotechnology

EpilepsyGTx raises $33 million Series A to advance single-dose gene therapy for focal refractory epilepsy

Montagu and Kohlberg Agree to Acquire Teleflex Medical OEM for $1.5 Billion

Most Read

Linus Health appoints Julie Wood, MD, MPH, FAAFP, as senior medical director for clinician engagement

Fondazione Telethon, Orphan Therapeutics Accelerator outline non-profit pathway for U.S. access to ultra-rare gene therapy

Sōlaria Biō study links gut barrier health, inflammation and bone density in breakthrough findings

DexCare Appoints Rakshay Jain as Chief Product Officer to Advance Patient Navigation Platform

EDITOR PICKS

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

THIS WEEK'S STORIES

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

Vertex Showcases New CASGEVY Data, Including First Results in Children Ages 5–11, and Prepares Global Regulatory Filings

Phare Bio and Basilea form partnership to develop AI-designed broad-spectrum antibiotic

POPULAR CATEGORY

ABOUT US

FOLLOW US